Biologics and JAK inhibitors in patients with IRD, including rates and ORs of hospitalization in relation to undergoing treatment.
| All Patientsa, n | Hospitalized Patients, n | Hospitalization Rate, % | OR* | 95% CI* | |
|---|---|---|---|---|---|
| IRD patients without biologics/JAK inhibitors | 3709 | 28 | 0.75 | 1 | |
| Anti-TNF | 603 | 4 | 0.66 | 0.88 | 0.31–2.50 |
| RTX | 72 | 7 | 9.72 | 12.88 | 5.82–28.51 |
| ABA | 40 | 1 | 2.50 | 3.31 | 0.46–23.75 |
| JAK inhibitors | 18 | 1 | 5.55 | 7.36 | 1.06–51.22 |
| Others | 150 | 0 | 0 | 0 |
↵a Hospitalized and nonhospitalized patients, diagnosed with IRD and monitored by the Department of Rheumatology.
↵* Comparisons were between each treatment group and IRD patients without biologic/JAK inhibitor treatment. ABA: abatacept; IRD: inflammatory rheumatic disease; JAK: Janus kinase; RTX: rituximab; TNF: tumor necrosis factor.